Multidrug resistance (MDR), a significant impediment to the successful treatment of cancer clinically, has been attributed to the overexpression of P-glycoprotein (P-gp), a plasma membrane multidrug efflux transporter. P-gp maintains sublethal intracellular drug concentrations by virtue of its drug efflux capacity. The cellular regulation of P-gp expression is currently known to occur at either pre-or post-transcriptional levels. In this study, we identify a 'non-genetic' mechanism whereby microparticles (MPs) serve as vectors in the acquisition and spread of MDR. MPs isolated from drug-resistant cancer cells (VLB 100 ) were co-cultured with drug sensitive cells (CCRF-CEM) over a 4 h period to allow for MP binding and P-gp transfer. Presence of P-gp on MPs was established using flow cytometry (FCM) and western blotting. Whole-cell drug accumulation assays using rhodamine 123 and daunorubicin (DNR) were carried out to validate the transfer of functional P-gp after co-culture. We establish that MPs shed in vitro from drug-resistant cancer cells incorporate cell surface P-gp from their donor cells, effectively bind to drug-sensitive recipient cells and transfer functional P-gp to the latter. These findings serve to substantially advance our understanding of the molecular basis for the emergence of MDR in cancer clinically and lead to new treatment strategies which target and inhibit MP mediated transfer of P-gp during the course of treatment.
Introduction
The over-expression of P-glycoprotein (P-gp) is one of the most widely observed mechanisms contributing to multiple drug resistance (MDR).
1-3 P-gp, encoded by the human MDR1 gene, also called ABCB1, is a 170 kDa plasma membrane Mg 2 þ -dependent ATPase which uses the energy released from ATP hydrolysis to efflux drug substrates across cell membranes. P-gp is a promiscuous drug transporter with a remarkable capacity to bind and transport a wide array of structurally and functionally unrelated compounds. Drug substrates include anticancer agents, typical and atypical antipsychotics; linear and cyclic peptides, fluorescent dyes, g-emitting radiopharmaceuticals and many other miscellaneous agents. 4 P-gp transport function is likewise modulated by a broad repertoire of agents.
5
MDR1 gene expression is a predictive index for anticancer treatment failure being correlated with lower remission and survival rates in acute myeloid leukemia, 6, 7 acute lymphoblastic leukemia, 8 soft tissue sarcoma, 9,10 neuroblastoma, 11 osteosarcoma, 12 ovarian and breast cancer. [13] [14] [15] Tumors showing innate drug resistance upon presentation include tumors of the colon, pheochromocytoma, renal cell, hepatocellular and pancreatic carcinomas. These tumors inherently express high levels of P-gp and consequently fail to respond to primary treatment. MDR1 gene expression is also induced during therapy and contributes significantly to acquired MDR observed in many malignancies.
Regulatory control of P-gp expression occurs at either pre-or post-transcriptional levels. Modulation at the level of protein and mRNA stability, plasma membrane incorporation, mRNA processing, gene amplification and transcription have all been shown for P-gp. [16] [17] [18] Recently a 'non-genetic' basis for the acquisition and spread of P-gp has been reported, both in vitro and in vivo, and raises questions on the mechanism regulating cell surface protein expression and the spread of MDR. 19 Levchenko and co-workers elegantly showed for the first time the intercellular transfer of functional P-gp from P-gp expressing donor cells to drug-sensitive recipient cells. 19 In their work, this protein transfer was proposed to be the result of direct membrane contact between both cell populations and/or large vesicles in excess of 0.8 mm rather than paracrine signaling. This prompted us to investigate the potential involvement of plasma membrane microparticles (MPs), defined typically as averaging a size of 500 nm, 20 as vectors in the intercellular transfer of P-gp. From this perspective, the direct role of MP in mediating P-gp transfer remains undefined.
Microparticles are small membrane vesicles (0.1-1 mm in diameter) derived from the ubiquitous cellular phenomenon of membrane budding. 21, 22 MP are released from the plasma membranes of various cell types, including platelets, macrophages, monocytes, T-cells, endothelial cells and erythrocytes. 23 Once considered 'inert side-products' of cellular activation, MP have become important mediators of inflammation, coagulation and vascular homeostasis. 24 MP are released upon cellular activation or during late apoptosis after a loss of membrane asymmetry and remodeling of the cytoskeleton. 21 MP carry surface antigens, proteins and adhesion molecules from their originating cell 25 and can mediate intercellular cross-talk by transferring receptors, antigens and cytokines from donor to recipient cells. 20, 21 The presence of cell adhesion molecules on MP supports a capacity for targeted cell binding and cell-cell interactions. 25 Here we show for the first time that purified MP transfer functional P-gp from resistant cancer cells to drug-sensitive cells in vitro and discuss the clinical implications of these findings in the emergence and treatment of acquired MDR in cancer.
Materials and methods

Cell lines
The drug sensitive parental human acute lymphoblastic leukemia cell line CCRF-CEM, and its MDR subline VLB 100 , referred to as MDR À and MDR þ cells, respectively, were employed for these studies and have been validated earlier by us as an appropriate model for the study of P-gp-mediated MDR in vitro. 26 MDR þ cells overexpress functional cell surface P-gp relative to the parental drug-sensitive CCRF-CEM cells. 27 
MP harvesting and identification
MP were isolated from confluent MDR þ cells by centrifugation, as described earlier, 28 and were designated MDR þ MP. Briefly, cell supernatant was isolated and centrifuged at 500 g for 5 min to pellet the cell population. Supernatant was further centrifuged at 13 000 g for 2 min to remove dead cells and debris. The clarified supernatant was spun at 24 000 g for 1 h at 15 1C to pellet the MP. The pellet was resuspended in the appropriate buffer. Identification of these isolated MP was carried out using FCM (Cytomics FC500 MPL, Beckman Coulter) following FITC-annexin V (Beckman Coulter) staining as described earlier by us. 28 
SDS-PAGE and western blotting
MDR
þ cells and isolated MDR þ MP were harvested and washed twice in phosphate buffered saline (PBS). The samples were lysed in CelLytic M Cell Lysis reagent (Sigma-Aldrich, NSW, Australia) in the presence of 1% (v/v) protease inhibitor cocktail (Sigma-Aldrich, NSW, Australia) on ice according to the manufacturers recommendation. The lysates were centrifuged at 10 000 g for 10 min at 4 1C. Total protein content was quantified using the BIO-RAD DC protein assay kit (BIO-RAD, NSW, Australia). 40 mg of total protein were separated by electrophoresis using a 4-12% NuPAGE Bis-Tris gel (Invitrogen, VIC, Australia) at a constant voltage of 200 V for 50 min. Anti-P-gp mAb, F4 and anti-b-tubulin antibody were used for western blotting (Sigma). The enhanced chemiluminescence (ECL) was carried out according to the manufacturer's recommendation (Roche Diagnostics, NSW, Australia).
Binding of MP to MDR À cells
After purification, MDR þ MP were labeled with PKH26 red dye according to the manufacturer's recommendation (SigmaAldrich, NSW, Australia) and designated as PKH26-MP. 5 Â 10 5 MDR À cells were susequently co-incubated with PKH26-MP for 2 h at 37 1C in complete RPMI-1640. After coincubation, cells were washed with PBS and centrifuged at 300 g for 5 min to remove unbound MP. The cells were re-suspended in 300 ml PBS and analyzed using both FCM and fluorescence microscopy (Olympus IX71 inverted fluorescence microscope) at 100 Â magnification. Images were acquired using the F-View high-definition black and white camera (Olympus) and analyzed using analySIS LS Research software (Olympus) after pseudo-coloring.
MP-mediated transfer of P-gp from resistant cells to sensitive cells
To examine MDR þ MP transfer of P-gp to MDR À cells, 1 Â 10 5 MDR À cells were co-incubated with MDR þ MP for 4 h in 96-well U bottom culture plates in 150 ml complete RPMI culture medium at 37 1C. After co-incubation, MDR À cells were collected by centrifugation and washed twice in PBS at 300 g, 5 min, 25 1C. Cells were labeled with either 20 ml FITC-anti P-gp (clone17F9, BD Pharmingen, NSW, Australia) or FITCÀisotype control mAb (BD Pharmingen) and incubated for 30 min at room temperature in the dark. The cells were again washed twice in PBS as described above. The cells were then resuspended in 200 ml PBS and analyzed by FCM. 
Functional assay
Statistical analyses
Means between groups were compared using a one-way analysis of variance (ANOVA) followed by a secondary test (Tukey) to compare the groups two by two. P-values o 0.05 were accepted as significant. All statistical analyses were carried out using GraphPad Prism version 5.0 for Windows Software (San Diego, CA, USA).
Results
Characterization and quantification of MDR þ derived MP
The drug-sensitive parental human acute lymphoblastic leukemia cell line CCRF-CEM, named MDR À and its multi-drug resistant sub-line VLB 100 , named MDR þ were employed for these studies. MP were purified from confluent MDR þ cells by a two-step centrifugation, as described earlier, 28 and designated MDR þ MP. Enumeration of isolated MP was carried out using flow cytometry (FCM) after FITC-annexin V staining as described. 28 The results indicate for the first time that MP are spontaneously shed from MDR þ cells (Figure 1 ). The population was defined as gated events smaller than 1 mm in diameter ( Figure 1a , MP gate). As shown in Figure 1b , MDR þ MP were identified as FITC-annexin V positive events as described earlier 28 and represented 70.8% of the gated population. To establish that MDR þ MP incorporated P-gp, both western blot analysis and immunodetection followed by FCM were conducted on purified MDR þ MP suspensions. P-gp was identified at 170 kDa on both MDR þ and MDR þ MP lysates consistent with the presence of P-gp in the isolated MP (Figure 1c) . Cell surface localization of P-gp was established in Figure 1d whereby 26% of gated MDR þ MP were detected positive for FITC-P-gp mAb (Figure 1d ). These results establish that the process of membrane budding and subsequent vesiculation incorporates P-gp within the MP membrane.
Binding of MP from MDR þ cells to MDR À cells
Before evaluating the possibility of MP-mediated transfer of P-gp from donor to recipient cells, we sought to first establish that MP bind to the recipient MDR À cells. Red fluorescent amphiphilic cell linker dye, PKH26 irreversibly intercalates between lipid in cell membranes without affecting cell growth or viability. This dye allows the identification of labeled cells among heterogeneous populations by FCM. MDR þ MP were isolated as described above, labeled with PKH26 and co-incubated with MDR À cells for 2 h at 37 1C in complete RPMI. After co-incubation, both PKH26-labelled MDR þ MP and cells were washed thoroughly, resuspended in PBS and analyzed by FCM (Figures 2a and c, respectively ) in parallel to fluorescence microscopy (Olympus IX71) at 100 Â magnification (Figures 2b  and d, respectively) . (Figure 3a , black open histograms), whereas no detectable P-gp was observed for the MDR À (Figure 3b , gray histograms). MDR À cells co-cultured with MDR þ MP for 4 h showed a cell surface P-gp expression in 14.8% of this population (Figure 3c , gray histograms). Similarly, P-gp transfer was observed as early as 2 h co-culture (data not shown).
Transferred P-gp is functional
To investigate whether the transferred protein was functional, drug accumulation assays were carried out using two structurally and functionally unrelated P-gp fluorescent substrates, rhodamine 123 (R123) and daunorubicin (DNR), commonly used in the assessment of the MDR phenotype. 29, 30 Although a 2 h co-culture period was sufficient to allow the transfer of P-gp from MDR þ MP to MDR À cells, it did not significantly confer a functional phenotype (data not shown). MDR À cells were thus co-cultured with MDR þ MP for 4 h. R123 accumulation was assessed in both MDR À and MDR þ cells in the presence or absence of the classic P-gp inhibitor, verapamil ( 28 Latex beads of 0.8 and 1.1 mm (Sigma) were used to define the upper limit of the forward scatter. The threshold was set on the side scatter to prevent exclusion of the smallest events. 28 The MP gate was confirmed to exclude whole cells and large debris after cell spiking of MP suspensions with non-purified whole in R123 accumulation in the MDR À /MDR þ MP cells compared with the MDR À cells alone (Figure 4c , Po0.0001). In the presence of verapamil, inhibition of P-gp resulted in a significant increase in R123 accumulation in the MDR À /MDR þ MP cells relative to untreated co-cultured cells (Figure 4c , Po0.0001). Similar patterns were also observed when assessing DNR accumulation indicating that the acquired phenotype upon coculture with MDR þ MP results in cross resistance to functionally distinct drugs (data not shown).
Discussion
In this report, we present the first evidence for a MP-mediated transfer of functional P-gp from drug-resistant cancer cells to drug-sensitive cells. MP have been earlier shown to be important mediators in the intercellular transfer of cell surface proteins in other pathologies. 20, 25 To our knowledge, this is the first demonstration of transfer of functional P-gp to drugsensitive recipient cells through purified MP resulting in the acquisition of MDR in cancer. It is also the first demonstration that MP can effectively incorporate and transfer an integral membrane protein of significant molecular weight.
Here we report that MDR þ cancer cells spontaneously shed membrane vesicles bearing morphological and phenotypical characteristics of MP showing typical submicron size and exposure of phosphatidylserine as shown in Figure 1 . 20, 22 In addition, these MP carry cell-surface P-gp from their originating MDR þ cells, effectively bind to drug-sensitive recipient cells and transfer functional cell surface P-gp from MDR þ cells to MDR À cells. The MP-mediated transfer of functional P-gp conferred to the recipient cells the MDR phenotype allowing drug-sensitive cells to extrude different drug substrates and hence maintain an intracellular drug accumulation deficit.
Induction of the MDR1 gene has been earlier shown to occur after exposure to various stresses, including carcinogens, cocarcinogens, 31, 32 antineoplastic agents, 33 differentiating agents, 34 protein kinase C activators 35 or heat shock. 36 MP incubation with drug-sensitive CCRF-CEM (MDR À ) cells may itself constitute a form of 'stress' resulting in an increase in transcription. MDR1 transcriptional induction typically shows a time and concentration dependence, peaking anywhere between 8-72 h after xenobiotic exposure in most cells, including the CCRF-CEM cells. [37] [38] [39] [40] For these cells, long-term drug exposure is required to overcome translational block and to express P-gp on their surface. 41 Consequently, considering the time frames used in this manuscript (2-4 h co-culture periods), it is more likely that we are observing exogenous P-gp being transferred to the parental cells through MPs rather than induction of transcription, translation and subsequent trafficking to the plasma membrane from intracellular compartments. Interestingly, we observe a discrepancy between the 14.8% of MDR À cells that show cell-surface P-gp after MDR þ MP binding (Figure 3c ) and the uniform population shift in R123 accumulation seen in Figure 4 . Given that only 26% of the isolated MP detected positive for P-gp by FCM (Figure 1 ), while at the same time we observe a 92.9% binding of PKH26-MP to MDR À cells (Figure 2b) . It seems that we may be underestimating the extent of P-gp transfer. Although FCM is the method of choice for studying MPs, 21, 42 the level of detection is dependent on size, level of expression and distribution of the antigen on the surface. In the case of MDR þ MP, immunodetection of P-gp by FCM may be limited in this aspect. This is further supported by the observed population shift for R123 accumulation indicative of a uniform presence of P-gp within the cell population (Figure 4) .
Circulating MP are important mediators of inflammation, coagulation and vascular homeostasis. MP are also shed by both hematological malignant cells, solid tumors in vitro and in vivo and have been implicated in tumor cell invasiveness, 43 escape from immune surveillance, 44 angiogenesis 45 and contribute to the hypercoagulable state observed in many malignancies. 43, 44, 46, 47 Our findings for a role of MP in the acquisition and spread of P-gp mediated MDR, thus defines a new clinical significance for MP in cancer-cell biology.
As MP of cancer-cell origin have been found in the plasma of patients, it is forseeable that MDR þ shed vesicles would contribute to the emergence and dissemination of MDR both in systemic disease and in distant metastatic clones from a primary tumor mass. Based on the nature of MP, namely their composition and their plasma membrane origin, our results suggest that MP could be a new mechanism for the 'non-genetic' acquisition of MDR. However, this proposal needs to be further analyzed in order to show the transient nature of the transfer that would be compatible with this hypothesis. The transient resistance established by this process has the potential to give drug-sensitive cells a survival advantage, an initial barrier to extreme xenobiotic exposure while the cells adapt their cellular machinery for more permanent mechanisms of survival.
These findings have potential to serve as a basis for the rational design of new treatment strategies which target and inhibit MP-mediated transfer of proteins implicated in the emergence of MDR during the course of treatment. Although current pharmacological inhibitors deal with MDR cost effectively, there exist problems of specificity, toxicity and differential modulation 26 with current strategies. MP inhibitors would provide an alternative treatment strategy 48, 49 with the added benefit of also targeting other MP associated complications observed in cancer clinically. In this regard, these findings have potential to translate into fundamental outcomes in the science and practice of clinical oncology.
